Researchers from Hangzhou Medical College in China have reported an interesting trend in global Clostridioides difficile infection (CDI) occurrences in hospitals during the COVID-19 pandemic compared to pre-pandemic periods, as demonstrated in their systematic review and meta-analysis published in Antimicrobial Resistance & Infection Control. In their analysis of 16 studies released between December 2019 and October 2025, the researchers concentrated on CDI incidence in tertiary hospitals located in high-income countries, most notably being the United States and Spain. Their findings have highlighted the resultant variability in the impact of the pandemic on CDI, a potent diarrheal disease.
Surprisingly, this impact discrepancy can be attributed to a multi-faceted set of factors during the pandemic. Few studies present climb in CDI occurrences while others report a significant downtick, establishing the need for a consolidated examination of these effects. The comprehensive evidence points towards a total 20% decrease in the pooled incidence rate of CDI, going from 4.42 per 10,000 patient-days pre-pandemic to 3.80 per 10,000 patient-days during the pandemic (incidence rate ratio, 0.80).
A deeper dive into these studies throws light on the combination of changes that resulted in this observed reduction, namely, effective changes in infection prevention and control, both antimicrobial stewardship and healthcare delivery. Public health emphasis on rigorous hand hygiene, judicious utilization of personal protective equipment, upped environmental cleaning, and reduced usage of fluoroquinolones would have impacted the CDI transmission and reduced selective pressure on some C. diff strains. Astonishingly, healthcare actions such as hospital stays being shortened, fewer elective procedures, and a drop in surgical volume could have led to contained patient exposure.
Despite the increased risk of CDI and other healthcare-associated infections due to amplified use of broad-spectrum antibiotics, resource constraints, and diagnostic challenges during the pandemic, the authors of this study credit the decline in CDI incidence to the application of strengthened foundational infection control practices. In other news, the European Commission is backing the fight against antimicrobial resistance (AMR) by making a €30 million investment into two public-private partnerships. These funds from the Commission’s DG Health Emergency Preparedness and Response Authority (DG HERA) will empower the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Global Antibiotic Research and Development Partnership (GARDP) in their respective missions to galvanize both early-stage and late-stage novel antibiotic R&D.
This initiative focuses on the need for comprehensive and sustainable countermeasures against AMR in the European Union, an area severely impacted by drug-resistant infections amounting to around 35,000 annual fatalities.